News

INmune Bio Embraces Growth with Q3 2024 Financial Highlights

INmune Bio Embraces Growth with Q3 2024 Financial Highlights

INmune Bio: Quarterly Progress and Financial Overview

INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage company focused on inflammation and immunology, recently unveiled its financial results for the third quarter of 2024, showcasing significant progress within its clinical programs and financial stability. The Company is dedicated to developing innovative treatments that leverage the innate immune system's potential to combat various diseases.

Progress in Clinical Trials

The cornerstone of INmune Bio's current research is evident in its robust pipeline, highlighted by advancements in its two primary platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) and INKmune™. The Company remains committed to rigorous clinical studies aimed at addressing unmet medical needs.

DN-TNF Platform Achievements

One of the standout advancements is the successful completion of patient enrollment for its Phase 2 Alzheimer's Disease (AD) trial, designated as the AD02 trial. This trial aims to explore the efficacy of XPro™, a treatment designed to alleviate symptoms in patients with early-stage Alzheimer's characterized by elevated neuroinflammation. Enrollment was concluded after confirming that there are sufficient patients to achieve the trial's target of 201 participants, potentially exceeding this number through ongoing screenings.

Interim analyses from this trial show promising outcomes, indicating a strong correlation between the unique cognitive measure EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB). These findings are crucial as they validate the precision of EMACC as a cognitive endpoint, essential for future Alzheimer's trials.

INKmune™ and Safety Outcomes

In recent developments, INKmune™ has proven its safety and efficacy in increasing Natural Killer (NK) cell activity in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). Initial dosing cohorts in this Phase I/II CaRe PC trial have shown that patients demonstrate significant increases in circulating activated NK cells, with no reported significant adverse events. This underscores INmune Bio's commitment to providing patient-friendly treatment options.

Financial Highlights

The financial landscape for the quarter ending September 30, 2024, reflects robust growth against prior performance. The net loss attributable to common stockholders for the quarter was approximately $12.1 million, an increase compared to the $8.6 million loss in the same quarter of the previous year. This increase can be attributed primarily to heightened investment in research and development.

Investment in Innovation

Research and development expenses surged to about $10.1 million for Q3 2024, a significant rise from the $6 million reported for the same period last year, demonstrating INmune Bio's unwavering dedication to advancing its clinical offerings. In contrast, general and administrative expenses saw a decrease, dropping to $2.2 million from $2.6 million in the prior year.

Cash Position and Market Activities

As of September 30, 2024, INmune Bio maintained a solid cash and cash equivalent position of approximately $33.6 million, which supports ongoing clinical trials and operational capabilities. Furthermore, the Company successfully executed securities purchase agreements, raising approximately $13 million from institutional investors and insiders, enhancing its financial robustness.

Upcoming Goals and Strategies

INmune Bio is set to achieve several critical milestones in the upcoming months. Top-line data from the Phase 2 Alzheimer's trial is anticipated in the second quarter of 2025, while a Phase II trial of XPro™ for patients with treatment-resistant depression is set to commence in the latter half of 2024. The Company also aims to complete enrollment for the Phase I section of the INKmune™ trial for mCRPC by year-end.

About INmune Bio

Founded with the vision to redefine therapeutic approaches to chronic diseases, INmune Bio stands at the forefront of leveraging the body’s immune system in innovative ways. The Company operates under two primary platforms: the DN-TNF platform focuses on developing treatments targeting TNF-related disorders while INKmune™ aims to potentiate the body’s NK cells for enhanced anti-cancer activity. These complementary approaches exemplify INmune Bio's commitment to advancing precision medicine in oncology and immunotherapy.

Frequently Asked Questions

What is the main focus of INmune Bio?

INmune Bio focuses on developing innovative treatments that target the innate immune system to combat diseases, primarily through its DN-TNF and INKmune™ platforms.

What are the recent achievements in their clinical trials?

The recent achievements include the completion of patient enrollment for the Phase 2 Alzheimer's Disease trial and demonstrated safety of INKmune™ in increasing NK cell activity in cancer patients.

How did INmune Bio perform financially in Q3 2024?

INmune Bio reported a net loss of approximately $12.1 million, reflecting increased investments in research and development while maintaining a strong cash position of about $33.6 million.

What can we expect from INmune Bio in the near future?

Investors and stakeholders can expect top-line data from the Alzheimer's trial in early 2025, as well as the launch of a new Phase II trial for treatment-resistant depression.

How does INKmune™ work?

INKmune™ is designed to convert resting NK cells into tumor-killing memory-like NK cells, enhancing the patient’s immune response against various cancers without the need for extensive pre-treatment procedures.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Voting Rights and Shareholder Engagement

Updated Category News Views 81

Understanding Voting Rights and Shareholder Engagement In today's corporate landscape, voting rights play a crucial role in corporate governance. Companies are required to disclose their voting rights and the number of shares, allowing shareholders to engage meaningfully with the management. This article will delve into the intricacies of voting rights, and the relevant...

Continue Reading
Cornish Metals Advances with Court Approval for UK Transition

Updated Category News Views 160

Cornish Metals Gets Final Court Approval for UK Move Cornish Metals Inc. (AIM/TSXV: CUSN) is thrilled to share that it has obtained a final order from the Ontario Superior Court of Justice. This landmark decision supports the company's plan to re-domicile from Canada to the United Kingdom through a statutory plan of arrangement, thus paving the way for an exciting new...

Continue Reading
Labubu's Rise: Challenging Mattel's Barbie in Toy Industry

Updated Category News Views 221

Pop Mart's Labubu Surges Towards Billion-Dollar Success Mattel Inc.'s iconic dolls, including Barbie and Hot Wheels, find themselves in a competitive landscape transformed by Pop Mart's innovative Labubu toy brand. This vibrant brand is racing towards remarkable financial achievements, aiming for a valuation that could reach four billion dollars by the year’s end. The...

Continue Reading
Tesla's Elusive Recovery in China: Challenges and Market Shift

Updated Category News Views 356

Tesla's Delivery Challenges in China Tesla Inc (NASDAQ: TSLA) recently faced a notable setback with a 13.5% year-over-year decline in vehicle deliveries during the second quarter. This decline raises questions about the company's performance in the critical Chinese market, a pivotal source for deliveries. The Decline in Numbers Data from the China Passenger Car...

Continue Reading
Alamos Gold Unveils Exciting Developments at PDA Project

Updated Category News Views 99

Alamos Gold Expands High-Grade Mineralization All financial figures mentioned are in United States dollars unless stated otherwise. Recently, Alamos Gold Inc. (TSX:AGI; NYSE:AGI), a prominent name in the mining industry, provided exciting updates regarding their ongoing drilling projects in the Mulatos District. The primary focus is on the Puerto Del Aire (PDA) and Cerro...

Continue Reading